Sector | Trading | Compare with Sector peers |
Industry | Trading | Compare with Industry peers |
Website | http://www.evoqremedies.com | |
Market Cap | 11.79 Cr. | |
Enterprise Value(EV) | 13.07 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.19 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 7.28 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 64.38 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 18.22 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 0.48 | Calculated using Price: 8.67 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.36 Cr. | 13,600,000 Shares |
FaceValue | 10 | |
About EVOQ Remedies Ltd. | ||
The company specializes in offering quality Pharmaceuticals Raw Material products, Excipients, and Bulk Drugs at an affordable prices. |
1 Day |
|
-5.23% |
1 Week |
|
-11.22% |
1 Month |
|
-32.08% |
3 Month |
|
-41.02% |
6 Month |
|
-41.22% |
1 Year |
|
-40.0% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 49.78 | 1.34 | 186.89 | 9.13 | 6.75 | |
Return on Capital Employed (%) | 68.94 | 2.69 | 246.9 | 9.12 | 6.96 | |
Return on Assets (%) | 0.52 | 0.01 | 10.45 | 5.27 | 4.75 |
Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 0 | 0 | 1 | 23 | 25 | 25 | |
Non Curr. Liab. | 0 | ||||||
Curr. Liab. | 2 | 6 | 7 | 10 | 10 | 6 | |
Minority Int. | |||||||
Equity & Liab. | 2 | 6 | 8 | 33 | 35 | 31 | |
Non Curr. Assets | 0 | 0 | |||||
Curr. Assets | 2 | 6 | 8 | 33 | 35 | 31 | |
Misc. Exp. not W/O | |||||||
Total Assets | 2 | 6 | 8 | 33 | 35 | 31 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 3 | 9 | 10 | 17 | 20 | |
Other Income | 6 | |||||
Total Income | 3 | 9 | 10 | 17 | 26 | |
Total Expenditure | -3 | -9 | -9 | -15 | -24 | |
PBIDT | 0 | 1 | 1 | 2 | ||
Interest | ||||||
Depreciation | ||||||
Taxation | 0 | 0 | -1 | |||
Exceptional Items | ||||||
PAT | 0 | 1 | 1 | 2 | ||
Adjusted EPS | 10 | 1 | 1 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | -26 | -4 | |
Cash Fr. Inv. | 0 | |||||
Cash Fr. Finan. | 29 | 1 | ||||
Net Change | 0 | 0 | 0 | 3 | -3 | |
Cash & Cash Eqvt | 0 | 0 | 3 | 0 |
Thu, 29 Feb 2024
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report Scrutinizer Report for Extra Ordinary General Meeting held on 28.02.2024 |
Wed, 28 Feb 2024
Shareholder Meeting / Postal Ballot-Outcome of EGM Outcome and Summary of Extra Ordinary General Meeting held today i.e. 28th February 2024 |
Wed, 07 Feb 2024
Reg. 34 (1) Annual Report. Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are submitting herewith the Revised Annual Report for Financial Year 2021-22 due to discrepancy related to Related Parties Transactions in the Audit report.Further this is to inform you that we were already submitted Annual Report for the Financial Year 2021-22 for the rectification the discrepancy we are submitting this revised Annual Report.There is no change in Annual Report other than Addition in Annexure in Directors report i.e. Annexure 3 and Disclosure of Related Parties transactions.Kindly take this revised Annual Report on your record and oblige us.Thanking You. |
Thu, 28 Mar 2024 |
High Delivery Percentage |
Close Crossing 52 Week Low |
Closing Below Previous Low |
Closing Below Previous Low for 3 days |
Making Lower Lows for 3 days |